AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
4.360
+0.080 (1.87%)
At close: Apr 24, 2026, 4:00 PM EDT
4.340
-0.020 (-0.46%)
After-hours: Apr 24, 2026, 4:10 PM EDT
AN2 Therapeutics Employees
AN2 Therapeutics had 21 employees as of December 31, 2025. The number of employees decreased by 1 or -4.55% compared to the previous year.
Employees
21
Change (1Y)
-1
Growth (1Y)
-4.55%
Revenue / Employee
n/a
Profits / Employee
-$1,674,952
Market Cap
156.22M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | -1 | -4.55% | 21 | 0 |
| Dec 31, 2024 | 22 | -19 | -46.34% | 22 | 0 |
| Dec 31, 2023 | 41 | 5 | 13.89% | 41 | 0 |
| Mar 31, 2023 | 36 | 14 | 63.64% | 35 | 1 |
| Dec 31, 2022 | 36 | 14 | 63.64% | 35 | 1 |
| Sep 30, 2022 | 27 | 5 | 22.73% | 26 | 1 |
| Jun 30, 2022 | 25 | - | - | 25 | 0 |
| Mar 31, 2022 | 22 | - | - | 22 | 0 |
| Dec 31, 2021 | 22 | - | - | 22 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| ProQR Therapeutics | 187 |
| Humacyte | 184 |
| Fate Therapeutics | 161 |
| Molecular Partners AG | 134 |
| Alps Group | 93 |
| Agenus | 81 |
| Spero Therapeutics | 25 |
| TuHURA Biosciences | 22 |
ANTX News
- 25 days ago - AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease - Business Wire
- 5 weeks ago - AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights - Business Wire
- 6 weeks ago - AN2 Therapeutics Stock Cools Off After 90% Rally - Benzinga
- 6 weeks ago - AN2 Therapeutics Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action? - Benzinga
- 6 weeks ago - AN2 Therapeutics Announces $40 Million Private Placement Financing - Business Wire
- 7 weeks ago - AN2 Therapeutics Transcript: Status update - Transcripts
- 7 weeks ago - AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV) - Business Wire